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A friend calls you just hours after the unexpected birth of his
son at 28 weeks gestation. He tells you the neonatologist
would like to transfer his child to a center that has the ability
to perform high-frequency oscillatory ventilation (HFOV). He
requests your advice on the decision.
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Abstract
Arguably one of the most important advances in critical care medicine in recent years has been the
understanding that mechanical ventilators can impart harm and that lung-protective ventilation
strategies can save lives. High-frequency oscillatory ventilation appears ideally suited for lung
protection at first glance. Two camps of opinion exist, however, even in neonates where this modality
has been most extensively studied. In the present debate, the prevailing arguments from each of those
camps are made available for the reader to decide.
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The scenario
Pro: Yes, HFOV is better than conventional ventilation for premature infants
Sherry E Courtney, David J Durand and Jeanette M Asselin
Despite recent advances in perinatal and neonatal care, some
very low birth weight infants still require prolonged mechani-
cal ventilation. Providing optimal mechanical ventilation is
thus an essential part of the care of very low birth weight
infants. There is considerable debate, however, about what is
‘optimal’ mechanical ventilation.
Animal data from the past 20 years clearly support the superi-
ority of HFOV over conventional ventilation (CV) [1–3]. HFOV
is synergistic with surfactant [4,5]. Compared with conven-
tional ventilators, HFOV decreases the levels of some inflam-
matory mediators in tracheal lavage fluid [6,7]. Most impor-
tantly, lung injury from chronic lung disease (CLD) is less with
HFOV than with CV [1,8].
Data from clinical trials have been less clear, due mainly to the
complexities of performing well-controlled ventilator trials in
human infants. Many studies have not employed an appropri-
ate lung recruitment strategy with HFOV. Until recently HFOV
has been used as only a ‘rescue’ technique, based largely on424
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concerns about its possible contribution to intraventricular
hemorrhage and/or periventricular leucomalacia [9]. However,
the concern about whether HFOV use leads to increased
intraventricular hemorrhage and periventricular leucomalacia
has finally been laid to rest with the recent publication of two
large multicenter trials, neither of which showed any increase
in these morbidities [10,11].
HFOV may be provided by a variety of ventilators. Importantly,
these machines have well-documented and substantial varia-
tions in their performance, making it impossible to compare
studies that do not use the same high-frequency device [12,13].
The differences in the outcomes of recent trials of HFOV may
be largely due to differences in the devices used.
Early use of HFOV employing a lung recruitment strategy has
been studied in several recent large clinical trials. Two of
these studies — one that employed HFOV using the Infant
Star High Frequency Ventilator (Nellcor Puritan Bennett Inc,
Carlsbad, CA, USA) [14], and one that employed predomi-
nantly the Drager Babylog 8000 (Drager Medizintechnik,
Lubeck, Germany) or the SLE 2000HFO (SLE Life Support,
South Croydon, Surrey, UK) [11] — found no differences in
pulmonary outcome of HFOV-treated infants compared with
infants treated with CV.
In contrast, two large studies that employed HFOV provided
by the SensorMedics 3100A (SensorMedics Inc, Yorba
Linda, CA, USA) found that infants randomized to HFOV had
less chronic lung disease compared with infants randomized
to CV [10,15]. Infants on HFOV in the trial by Gertsmann
et al. [15] also required less surfactant, and fewer infants
required prolonged oxygen or ventilator support. In followup
at a mean age of 6 years, patients in this study who random-
ized to CV showed worse pulmonary function than children
who had been randomized to HFOV [16]. In the trial by
Courtney et al., which compared HFOV with a sophisticated
CV strategy including both continuous tidal volume monitor-
ing to avoid lung injury from volutrauma and protocolized
weaning, HFOV infants fared significantly better than CV
infants. In this trial, infants on HFOV were extubated, on
average, a full week earlier than infants on CV, and had a
lower incidence of CLD [10].
Data available to date thus suggest that early use of HFOV,
when provided by the SensorMedics 3100A and utilizing an
appropriate strategy, can lead to earlier extubation, to a
decrease in CLD, and to improved long-term outcome in the
very low birth weight infant. We would support the transfer of
patients at high risk of needing prolonged ventilation and/or
developing CLD to a center that can provide effective HFOV.
Con: No, HFOV is not better than CV for premature infants
Eric C Eichenwald and Ann R Stark
Most infants born at 28 weeks gestation have respiratory
failure due to surfactant deficiency and require assisted venti-
lation. However, lung injury induced by assisted ventilation
contributes to the development of bronchopulmonary dyspla-
sia (BPD), an important cause of chronic illness in these
infants. Causes of lung injury include the repetitive expansion
and collapse of the lungs, and the delivery by conventional
mechanical ventilation of relatively large tidal volumes that
overdistend airways and airspaces. This suggests that a venti-
lator strategy that avoids large cyclic changes in lung volume
may reduce lung injury [3,17]. The application of HFOV in pre-
mature newborns has generated considerable interest
because this technique of rapid ventilation with very small tidal
volumes might prevent BPD.
In animal models of respiratory distress syndrome, HFOV
used with a strategy of optimizing lung inflation improved gas
exchange and lung mechanics, promoted more uniform infla-
tion, reduced air leak, and decreased the concentration of
inflammatory mediators in the lung, compared with conven-
tional mechanical ventilation [6]. Unfortunately, avoidance of
lung injury by HFOV in animal studies has not been replicated
in human preterm infants.
In five of the seven randomized trials comparing HFOV with
CV performed since replacement pulmonary surfactant
became available to treat respiratory distress syndrome, the
type of ventilation made no difference in the rate of survival
without BPD [11,14,18–20]. Two trials showed a small
benefit of HFOV in that outcome [10,15]. One included few
of the infants at highest risk and used relatively high ventila-
tor pressures with CV [15]. The other trial, conducted under
rigorously controlled conditions, is the only study that has
shown a benefit of HFOV in infants at high risk for BPD [10].
In addition to the lack of benefit found in most of the trials,
the rates of pulmonary air leak [10,14] and neurologic com-
plications may be higher in infants treated with HFOV
[19,20].
Despite the compelling animal data, HFOV has not been
clearly shown to be the ‘better’ mode of mechanical ventila-
tion for preterm infants for at least two reasons. First, most
neonatal intensive care units use conventional mechanical
ventilation as the routine mode of respiratory support. Thus,
clinical teams often are less experienced with HFOV. This
may place individual infants at greater risk for inadvertent
overdistention of the lungs, for impaired cardiac output, or for
increased central venous pressure that might lead to intracra-
nial hemorrhage. Second, the pathogenesis of BPD is
complex, and mechanical injury is only one factor. Other
factors that contribute to lung injury, such as delivery circum-
stances, initial resuscitation, and maternal or neonatal infec-
tion, may be more important than the mode of mechanical
ventilation in the pathogenesis of BPD [21].425
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Pro’s response
Sherry E Courtney, David J Durand and Jeanette M Asselin
We agree with Eichenwald and Stark that those who use
HFOV should be experienced with its use. As with any tech-
nology, it must be employed correctly to attain the best
results.
We do not agree that HFOV should be reserved for infants in
whom CV is failing. Using HFOV only for rescue means delay-
ing its use until volutrauma, barotrauma, and oxygen toxicity
have already occurred, making any response to HFOV less
likely. The most compelling trials of HFOV are those that
began HFOV early in the course and continued it until extuba-
tion [10,15,22,23]).
Con’s response
Eric C Eichenwald and Ann R Stark
We agree that early HFOV administered by experienced clini-
cians using strict protocols may provide a small pulmonary
advantage in some infants. Most trials, however, have shown
no advantage over CV, suggesting that pulmonary outcome
may be influenced more by factors other than the mode of ven-
tilation. Furthermore, any potential advantage must be
weighed against the known risks of neonatal transport, even
between tertiary centers. Transported infants have higher risks
of death [24,25], of intraventricular hemorrhage [25–27], and
of BPD [25] compared with infants treated in their birth hospi-
tals. We thus do not think transport just for the availability of
HFOV is justified.
In the most experienced centers, HFOV administered accord-
ing to strict protocols may offer a small pulmonary benefit in
infants at high risk for BPD [10]. However, the majority of
available evidence does not support this advantage. For most
preterm infants with respiratory distress syndrome, appropri-
ate management includes prompt resuscitation at delivery,
early administration of exogenous surfactant, and conven-
tional mechanical ventilation with low tidal volumes and rea-
sonable ventilation goals. In general, HFOV should be
reserved for infants in whom CV is failing.
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